In reaction to strong earnings/guidance: None
M&A related: SANW +35.2% ( to acquire DuPont Pioneer's alfalfa research and production assets for $42 mln), CACQ +1.3% (merging with CZR in all stock transaction) CZR +3.8% (merging with CACQ in all stock transaction).
A few Russia names are trading higher amid bounce in ruble, decline in bond yields there: QIWI +3.4%, YNDX +3%.
Other news: ACHN +14.5% (announced positive data on hepatitis C treatment), ENTA +21.2% (FDA approves AbbVie's (ABBV) Viekira Pak; ENTA is partnered with ABBV on drug), CYTX light volume +20% (on Friday morning co amended BARDA contract to accelerate thermal burn injury countermeasure), BCRX +10.2% (receives FDA approval for the treatment of acute uncomplicated influenza ), PLUG +5.6% (still checking), TASR +3.6% (announced multiple orders of its TASER brand next generation Smart Weapons and Conducted Electrical Weapons), NLNK +3.5% & Merck (MRK) announce collaboration to manufacture Ebola vaccine candidate supported by $30 mln government award), PBR +3.4% (still checking), CBST +2.1% (announces FDA approval of new antibiotic ZERBAXA).
Analyst comments: BBRY +2.1% (upgraded to Buy from Hold at TD Securities), RAD +1.8% (upgraded to Outperform from Market Perform at Cowen).
M&A related: SANW +35.2% ( to acquire DuPont Pioneer's alfalfa research and production assets for $42 mln), CACQ +1.3% (merging with CZR in all stock transaction) CZR +3.8% (merging with CACQ in all stock transaction).
A few Russia names are trading higher amid bounce in ruble, decline in bond yields there: QIWI +3.4%, YNDX +3%.
Other news: ACHN +14.5% (announced positive data on hepatitis C treatment), ENTA +21.2% (FDA approves AbbVie's (ABBV) Viekira Pak; ENTA is partnered with ABBV on drug), CYTX light volume +20% (on Friday morning co amended BARDA contract to accelerate thermal burn injury countermeasure), BCRX +10.2% (receives FDA approval for the treatment of acute uncomplicated influenza ), PLUG +5.6% (still checking), TASR +3.6% (announced multiple orders of its TASER brand next generation Smart Weapons and Conducted Electrical Weapons), NLNK +3.5% & Merck (MRK) announce collaboration to manufacture Ebola vaccine candidate supported by $30 mln government award), PBR +3.4% (still checking), CBST +2.1% (announces FDA approval of new antibiotic ZERBAXA).
Analyst comments: BBRY +2.1% (upgraded to Buy from Hold at TD Securities), RAD +1.8% (upgraded to Outperform from Market Perform at Cowen).